MCL1 and in situ carcinoma: Additionally, we found no significant differences in GILZ, MCL-1 and NOXA mRNA levels on PostMPD1 versus PostMPD5, neither in clinical responders nor in non-responders in CIS, RRMS and SPMS patients (Supplementary Table 1).